Corporate Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Mar 23, 2023
Mar 21, 2023
Mar 16, 2023
Events
Mar 28 - Apr 1, 2023
Mar 23, 2023 at 8:00 AM EDT
Mar 15, 2023 at 10:00 AM EDT
Latest SEC Filings
Form | Filing date | Description |
---|---|---|
D | Notice of Exempt Offering of Securities |
|
D | Notice of Exempt Offering of Securities |
|
D | Notice of Exempt Offering of Securities |